Document is current
Any future updates will be listed below
-
Authors
Knudsen, Hannah K.
Andrews-Higgins, Shaquita
Back-Haddix, Sandra
Lofwall, Michelle R.
Fanucchi, Laura
Walsh, Sharon L.
-
Funding
Funding for this research was provided by:
National Institutes of Health and the Substance Abuse and Mental Health Services Administration (UM1DA049406, UM1DA049406, UM1DA049406, UM1DA049406, UM1DA049406, UM1DA049406)
- License Information
-
More Information
Article History
Received: 12 November 2024
Accepted: 20 March 2025
First Online: 2 April 2025
Declarations
:
: This study protocol (Pro00038088) was approved by Advarra Inc., the HEALing Communities Study single Institutional Review Board. All participants provided verbal informed consent prior to being interviewed.
: Not applicable.
: HKK, SBH, SAH, and LF declare that they have no competing interests. In the last three years, ML has been a research consultant for Braeburn Pharmaceuticals, Berkshire Biomedical, and Journey Colab, and has received a speaker honorarium for an invited research talk from Camurus. SW has served as a scientific advisor to Cerevel Therapeutics, Astra Zeneca, Kinoxis, Reacx, Titan, and Braeburn Pharmaceuticals.
